Dr. Zhu previously worked in Dept of Biotransformation, Bristol-Myers Squibb (BMS) (Jan 1998-Dec 2016), where he and his team supported over 10 discovery programs, more than 15 development drug candidates, and worldwide approvals of ABILIFY (Aripiprazole) and FORXIGA (Dapagliflozin).

Dr. Zhu and his collaborators at BMS developed several innovative LC/MS workflows and data-mining technologies such as mass defect filter, background subtraction and multiple ion monitoring for drug metabolite detection and identification, which now are routinely used in drug metabolism research worldwide. Recently, his research interests have been expended to ADME strategy and method of unconventional drug modalities, such as ADC, cyclic peptides, herbal medicines, covalent drugs, stable isotope labeled drugs, prodrugs, protein therapeutics.